
EU Launches Public Consultation on Phthalates in Medical Devices
Stakeholders are encouraged to provide feedback on the preliminary guidelines by submitting written comments.

The European Commission's dedication to public health safety takes a significant step forward with the announcement of a public hearing by the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER). Scheduled for the 11 April, 2024, this event aims to address the presence of phthalates in certain medical devices, focusing on updating guidelines related to their benefit-risk assessment.
The hearing is part of a broader public consultation process, open from 27 March to 28 April 2024, allowing for a comprehensive collection of comments, suggestions, and scientific inputs on the guidelines. This initiative showcases the Commission's commitment to evidence-based policymaking and stakeholder engagement in health and safety regulations.
Phthalates, known for their flexibility-enhancing properties, are widely used in various products, including medical devices. Given their potential health risks, such as carcinogenic and endocrine-disrupting effects, their use in medical settings is being re-evaluated, leading to the need for updated safety guidelines.
The Brussels hearing will serve as a platform for scientists and technical experts to discuss scientific evidence concerning phthalates in medical devices. Emphasizing a scientific approach, the Commission has stated that the event will focus solely on scientific matters, explicitly prohibiting public relations or lobbying efforts.
Interested participants are required to register by the 17 March, 2024, with the event operating on a first-come, first-served basis due to limited space. The Commission has advised against making travel or accommodation arrangements until participation is confirmed, noting that it will not cover any related expenses.
This public hearing represents a key moment in the European Commission's efforts to ensure the highest health and safety standards for its citizens. It underscores the importance of scientific inquiry and public involvement in addressing emerging health risks. The final program and list of participants will be made available on the Scientific Committees' website, offering further insight into the event's objectives and significance.
For those invested in the regulatory landscape of medical devices and public health policy, the SCHEER public hearing on 11 April 2024, is a pivotal event marking the European Commission's proactive stance on health and safety concerns.




Stakeholders are encouraged to provide feedback on the preliminary guidelines by submitting written comments.

EU assesses Benzophenone-2 and Benzophenone-5 for endocrine-disrupting risks in cosmetics. Learn what this means for regulatory compliance.

AB 1604 proposes a 2027–2028 phase-out of intentionally added bisphenols in paper receipts, with enforcement by DTSC and civil penalties for violators.
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at